49. Systemic lupus erythematosus
827 clinical trials,   638 drugs   (DrugBank: 168 drugs),   108 drug target genes,   191 drug target pathways

Searched query = "Systemic lupus erythematosus", "SLE"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2005-004067-30-DE
(EUCTR)
05/10/200611/05/2006A Double Blind, Randomized, Placebo Controlled, Multi-Center Trial of Anti-TNFafa Chimeric Monoclonal Antibody (Infliximab, Remicade®) and Azathioprine in Patients Suffering from Systemic Lupus Erythematosus (SLE) with WHO Class V GlomerulonephritisA Double Blind, Randomized, Placebo Controlled, Multi-Center Trial of Anti-TNFafa Chimeric Monoclonal Antibody (Infliximab, Remicade®) and Azathioprine in Patients Suffering from Systemic Lupus Erythematosus (SLE) with WHO Class V Glomerulonephritis Systemic Lupus Erythematosus (SLE) with WHO Class V GlomerulonephritisTrade Name: Remicade
Product Name: Remicade
INN or Proposed INN: Infliximab
Trade Name: Azathioprine
Other descriptive name: Azathioprine
Department of Rheumatology, Internal Medicine III, Medical University of ViennaNULLNot RecruitingFemale: yes
Male: yes
44Germany;Netherlands;Austria
2NCT00368264
(ClinicalTrials.gov)
September 200623/8/2006TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL )A Double Blind, Randomized, Placebo Controlled, Multi-Center Trial of Anti-TNF-alpha Chimeric Monoclonal Antibody (Infliximab) and Azathioprine in Patients Suffering From Systemic Lupus Erythematosus (SLE) With WHO Class V GlomerulonephritisLupus Erythematosus, Systemic;Lupus NephritisDrug: infliximab;Drug: placeboMedical University of ViennaHospital Hietzing;Medical University of Graz;Charite University, Berlin, Germany;University of Erlangen-Nürnberg;Heinrich-Heine University, Duesseldorf;University Medical Centre Groningen;Leiden University Medical Center;Radboud UniversityTerminated18 YearsN/ABoth1Phase 2;Phase 3Austria;Germany;Netherlands
3EUCTR2005-004067-30-NL
(EUCTR)
08/08/200620/04/2006A Double Blind, Randomized, Placebo Controlled, Multi-Center Trial of Anti-TNFafa Chimeric Monoclonal Antibody (Infliximab, Remicade®) and Azathioprine in Patients Suffering from Systemic Lupus Erythematosus (SLE) with WHO Class V GlomerulonephritisA Double Blind, Randomized, Placebo Controlled, Multi-Center Trial of Anti-TNFafa Chimeric Monoclonal Antibody (Infliximab, Remicade®) and Azathioprine in Patients Suffering from Systemic Lupus Erythematosus (SLE) with WHO Class V Glomerulonephritis Systemic Lupus Erythematosus (SLE) with WHO Class V GlomerulonephritisTrade Name: Remicade
Product Name: Remicade
INN or Proposed INN: Infliximab
Trade Name: Azathioprine
Other descriptive name: Azathioprine
Department of Rheumatology, Internal Medicine III, Medical University of ViennaNULLNot RecruitingFemale: yes
Male: yes
44Germany;Netherlands;Austria
4EUCTR2005-004067-30-AT
(EUCTR)
08/05/200631/03/2006A Double Blind, Randomized, Placebo Controlled, Multi-Center Trial of Anti-TNFafa Chimeric Monoclonal Antibody (Infliximab, Remicade®) and Azathioprine in Patients Suffering from Systemic Lupus Erythematosus (SLE) with WHO Class V GlomerulonephritisA Double Blind, Randomized, Placebo Controlled, Multi-Center Trial of Anti-TNFafa Chimeric Monoclonal Antibody (Infliximab, Remicade®) and Azathioprine in Patients Suffering from Systemic Lupus Erythematosus (SLE) with WHO Class V Glomerulonephritis Systemic Lupus Erythematosus (SLE) with WHO Class V GlomerulonephritisTrade Name: Remicade
Product Name: Remicade
INN or Proposed INN: Infliximab
Trade Name: Azathioprine
Other descriptive name: Azathioprine
Department of Rheumatology, Internal Medicine III, Medical University of ViennaNULLNot RecruitingFemale: yes
Male: yes
44Germany;Netherlands;Austria